What is MOTS-c, and where does it come from?
MOTS-c stands for Mitochondrial Open Reading Frame of the Twelve SrRNA-c. It is a 16-amino-acid peptide encoded not in the nuclear genome — where the vast majority of human proteins originate — but within the 12S ribosomal RNA region of the mitochondrial genome. Its identification by Lee and colleagues in a 2015 Cell Metabolism study overturned a long-standing assumption that mitochondrial DNA encodes only components of the respiratory chain; it produces signaling peptides that circulate in the blood and regulate systemic metabolism.
MOTS-c is detectable in human plasma and skeletal muscle, and its circulating levels decline measurably with age. Older adults have significantly lower plasma MOTS-c than young adults — a pattern that parallels the metabolic changes associated with aging, including reduced insulin sensitivity and declining mitochondrial biogenesis. This age-related decline is the core mechanistic rationale behind interest in MOTS-c as a longevity-focused research compound. Whether replenishing MOTS-c in humans produces the metabolic benefits documented in rodent models has not yet been established in clinical trials.
How does MOTS-c work?
MOTS-c acts primarily through the folate-AICAR-AMPK signaling axis. AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) is an intermediate in the de novo purine biosynthesis pathway. In the original Lee et al. experiments, MOTS-c treatment produced more than a 20-fold increase in endogenous AICAR levels, which in turn activated AMP-activated protein kinase (AMPK). AMPK is a master energy sensor that, when activated, promotes skeletal muscle glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while suppressing energy-consuming anabolic processes.
This mechanism explains the preclinical findings: in mouse models, MOTS-c prevented high-fat-diet-induced weight gain, improved insulin sensitivity, and increased energy expenditure — effects that closely mirror what happens with exercise-driven AMPK activation, earning MOTS-c the informal description "exercise in a peptide" in some research commentary. MOTS-c also translocates to the cell nucleus under cellular stress, where it appears to modulate gene expression related to antioxidant response and metabolic adaptation. These are preclinical observations. Translation of rodent MOTS-c responses to human therapeutic outcomes has not been established in controlled clinical trials, and the compound should be understood as experimental.
What doses have been studied, and what do they tell us?
No human Phase 1 or Phase 2 clinical trials establishing safe and effective MOTS-c doses have been completed. The available dosing data come entirely from preclinical animal experiments:
In the seminal 2015 Lee et al. study, daily intraperitoneal injections of 15 mg/kg in mice prevented high-fat-diet-induced obesity and improved insulin sensitivity over a 4-week period. Vascular calcification models used 5 mg/kg once daily for four weeks to demonstrate AMPK-mediated protective effects. Some skeletal muscle studies have administered fixed doses of approximately 500 µg in mouse models investigating dystrophin expression and mitochondrial bioenergetics.
Rodent-to-human dose translation for peptides is not straightforward — it depends on pharmacokinetic parameters (bioavailability by route of administration, volume of distribution, metabolic clearance, and elimination half-life) that have not been characterized for MOTS-c in humans. Applying animal mg/kg doses directly to human protocols without those parameters is scientifically unjustified. This is precisely why Phase 1 dose-finding trials exist: to establish safe starting doses, characterize pharmacokinetics, and define dose-limiting toxicities in humans before therapeutic doses can be proposed. That work has not yet been done for MOTS-c.
Is MOTS-c FDA-approved, and is it safe to use?
MOTS-c is not FDA-approved for any indication as of 2026. It is not classified as a pharmaceutical, dietary supplement, or cosmetic under any existing FDA framework. It is a research-stage compound with no IND application, no NDA, and no completed human safety trials.
Online sources selling "MOTS-c research peptide" offer material that is not subject to FDA testing for identity, potency, sterility, or endotoxin content. For any injectable compound, unverified endotoxin levels carry real risk: endotoxin contamination can produce fever, systemic inflammation, and — in severe cases — septic-shock-like responses. The absence of regulatory oversight means there is no external guarantee about what the material actually contains, at what concentration, or how it was manufactured.
This does not mean MOTS-c is intrinsically hazardous — preclinical data suggest a generally favorable profile. It does mean that the safety margins, contraindications, and adverse-effect profile in humans are genuinely unknown. A licensed clinician supervising an investigational protocol, ideally within an IRB-approved framework, is the appropriate safeguard for any human exposure.
Tracking a MOTS-c protocol on PeptidePanel
PeptidePanel does not sell, source, supply, endorse, or prescribe MOTS-c or any compound, and nothing here is medical advice. If a licensed clinician is supervising an investigational MOTS-c protocol, tracking the intervention with the same rigor you would apply to an approved therapy is sensible practice: dose log with injection timestamps, relevant metabolic biomarkers (fasting glucose, insulin, HbA1c, IGF-1, inflammatory markers, weight and body composition trends), and any side-effect observations.
PeptidePanel is the neutral monitoring layer for that record-keeping. It logs the protocol as your clinician directs, charts bloodwork against reference ranges, and helps you and your prescriber see how the measured metrics change across the course of the protocol — the kind of longitudinal picture that turns anecdote into data.